Physician profile
Jack Farahi
NPI 1225034358
$10,413.92
in general payments reported to CMS, 2019-2025
39 companies · $1,664 in 2025
The $1,664 reported for 2025 was more than what 92% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,731 · 2020: $966 · 2021: $1,261 · 2022: $1,456 · 2023: $1,920 · 2024: $1,416 · 2025: $1,664.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,692 · Consulting Fee: $308.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,691.68 |
| Consulting Fee | $308.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,133.09 | 2019-2025 | |
| Amgen INC. | $710.34 | 2019-2023 | Evenity, Prolia, Repatha |
| Pfizer INC. | $685.70 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $580.65 | 2019-2025 | Wainua, Farxiga, Brilinta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $552.14 | 2023-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $539.61 | 2022-2025 | Verquvo, Winrevair |
| Alnylam Pharmaceuticals INC. | $539.29 | 2019-2025 | Amvuttra |
| Novo Nordisk INC | $521.23 | 2020-2025 | Ozempic, Wegovy |
| Esperion Therapeutics, INC. | $461.84 | 2020-2025 | Nexletol |
| Kestra Medical Technology Services, INC. | $446.87 | 2022-2025 | Assure Wcd |
| Sanofi-Aventis U.S. LLC | $409.90 | 2019 | |
| Janssen Pharmaceuticals, INC | $337.38 | 2019-2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $319.75 | 2019-2025 | |
| Abbott Laboratories | $282.32 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $282.09 | 2019-2025 | Camzyos, Eliquis |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Farahi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.